Breaking Research News from Breastcancer.org
Comments
-
A New Standard of Care? Enhertu Improves Survival in People With Metastatic HER2-Low Breast Cancer
June 6, 2022
Compared with doctors' choice of chemotherapy, Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) improved both progression-free survival and overall survival in people diagnosed with previously treated metastatic HER2-low breast cancer. Read more...0 -
Lying Facedown for Radiation Therapy Causes Fewer Skin Side Effects in Women With Large Breasts
June 2, 2022
During external whole-breast radiation therapy for breast cancer, women with large breasts who lay facedown had fewer skin side effects than women who lay faceup. Read more...0 -
Many Black Metastatic Breast Cancer Patients Never Informed About Clinical Trials
June 8, 2022
Many Black people diagnosed with metastatic breast cancer never find out about clinical trials from their doctors even though most of them are open to participating in one. Read more...0 -
Trodelvy Slightly Improves Progression-Free Survival for Pre-treated Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer
June 8, 2022
Trodelvy (chemical name: sacituzumab govitecan-hziy) slightly improved progression-free survival in people diagnosed with metastatic hormone receptor-positive, HER2-negative breast cancer previously treated with hormonal therapy, a CDK4/6 inhibitor, and multiple lines of chemotherapy. Read more...0 -
Well this is really discouraging news. Medical racism is real. All women get breast cancer. I hope this study helps to promote change in the process to promote more inclusiveness. Thanks for posting this study.
0 -
Thanks marigold -- we agree. We hope this incites change also!
0 -
Some Older Women With Luminal A Breast Cancer May Be Able To Skip Radiation After Lumpectomy
June 15, 2022
Women ages 55 and older diagnosed with early-stage, estrogen receptor-positive, progesterone receptor-positive, HER2-negative breast cancer that had low levels of Ki67 protein and a very low risk of recurrence were able to safely skip radiation after lumpectomy. Read more...0 -
After DCIS, About One in Five Invasive Breast Cancers Unrelated to Original DCIS
June 15, 2022
In the years following a DCIS (ductal carcinoma in situ) diagnosis, about one in five invasive breast cancers that developed were not related to the original DCIS lesion. Read more...0 -
Black and Hispanic Women May Have Higher Risk of Lymphedema
June 15, 2022
Among women who had breast cancer surgery and axillary lymph node dissection, Black and Hispanic women were more likely to develop lymphedema than white women, as were women who received chemotherapy before surgery, rather than after surgery. Read more...0 -
3D Mammograms Reduce Risk of Advanced-Stage Disease in Women With Extremely Dense Breasts and High Risk of Breast Cancer
June 15, 2022
In women with extremely dense breasts and a high risk of breast cancer, screening with 3D mammograms — rather than 2D digital mammograms — was linked to a lower risk of advanced-stage disease. Read more...0 -
Hormone-Free Medicine for Hot Flashes Shows Promise
June 21, 2022
Fezolinetant, an experimental medicine that doesn't contain hormones, has successfully treated hot flashes. Read more...0 -
Risk of Heart Problems Lower in Breast Cancer Survivors Who Exercise
Jun 27, 2022
Exercise helped reduce the risk of heart problems in women receiving treatment for breast cancer. Read more...0 -
Black Women Most Likely To Experience Biopsy Delays After Abnormal Mammogram
July 7, 2022
Women from various racial and ethnic backgrounds, particularly Black women, had a higher risk of biopsy delays after an abnormal mammogram than white women. Read more...0 -
Cancer Survivors Have Higher Risk of Cardiovascular Disease
July 11, 2022
Cancer survivors have a higher risk of developing cardiovascular disease, including heart failure and stroke, than people with no history of cancer. Read more...0 -
Giving Birth After Breast Cancer Doesn't Affect Survival
July 11, 2022
Having a baby after completing treatment for early-stage breast cancer doesn't negatively affect overall survival. Read more...0 -
Cases of Breast Implant-Related Cancer May Be More Than Double FDA Estimates
July 25, 2022
The number of U.S. cases of breast anaplastic large-cell lymphoma — a rare cancer linked to textured implants — may be twice as high as U.S. Food and Drug Administration estimates. Read more...0 -
HRT Doesn't Seem To Raise Risk of Breast Cancer Recurrence in Certain Women
July 28, 2022
Overall, neither systemic nor vaginal hormone replacement therapy (HRT) seemed to increase the risk of breast cancer recurrence (the cancer coming back) in women diagnosed with early-stage, estrogen receptor-positive disease. Still, using vaginal HRT slightly increased recurrence risk in women who received an aromatase inhibitor. Read more...0 -
Hearing Problems Common After Chemotherapy Treatment
July 28, 2022
Hearing loss and other hearing problems seem to be common in adults who've received chemotherapy for the four most common types of cancer, including breast cancer. Read more...0 -
Experimental Immunotherapy Medicine Works Similarly in Black and White Women With Triple-Negative Breast Cancer
Aug 4, 2022
When more Black women diagnosed with early-stage, triple-negative breast cancer joined a study on Imfinzi, the results showed the immunotherapy was as effective in Black women as it was in women of other races and ethnicities. Read more...0 -
Oral Paclitaxel Plus Encequidar Offers Better Response Than IV Paclitaxel in Metastatic Breast Cancer
Aug 4, 2022
Metastatic breast cancer responded better to a combination of the chemotherapy medicine paclitaxel in pill form and encequidar (a medicine that allows oral paclitaxel to be absorbed into the bloodstream) than to intravenous paclitaxel. Read more...0 -
FDA Approves Enhertu for Unresectable or Metastatic HER2-Low Breast Cancer
Aug 5, 2022
On Aug. 5, 2022, the U.S. Food and Drug Administration approved Enhertu to treat unresectable or metastatic HER2-low breast cancer. Read more...0 -
Knowing Moms' Hereditary Cancer Risk Doesn't Affect Kids' Quality of Life
Aug 8, 2022
Telling children that their mothers have a genetic risk of developing breast and ovarian cancer doesn't affect their long-term quality of life. Read more...0 -
Understanding How Mindfulness Meditation Reduces Pain
Aug 12, 2022
Mindfulness meditation seems to ease pain by allowing people to separate pain from things they're experiencing. Read more...0 -
Boost Dose After Radiation for Moderate- or High-Grade DCIS Reduces Recurrence Risk
Aug 15, 2022
After whole-breast radiation, a boost dose to the area where the tumor was further reduced the risk of moderate- or high-grade DCIS coming back. Read more...0 -
Piqray Linked to Colitis
August 22, 2022
Colitis has been identified as a new side effect of the targeted therapy Piqray. Read more...0 -
After Chemotherapy, Fatigue May Contribute More to Balance Problems Than Neuropathy
Aug 25, 2022
After receiving chemotherapy for breast cancer, women who had more severe, persistent fatigue were more likely to have balance problems, whether they had peripheral neuropathy or not. Read more...0 -
New NCCN Breast Cancer Screening Guidelines: Annual Mammograms Should Start at 40
Sep 7, 2022
Aiming to clarify when women should start having mammograms, the National Comprehensive Cancer Network has released new guidelines for breast cancer screening and diagnosis that say all women age 40 and older at average risk of breast cancer should have annual mammograms. Read more...0 -
Neurofeedback May Help Ease Chemo Brain
Sep 7, 2022
Neurofeedback — a type of therapy that uses a computer program to measure brain wave activity — shows promise for treating the mental fogginess many people have after chemotherapy. Read more...0 -
New CDK4/6 Inhibitor Offers Benefits for Advanced-Stage, Hormone Receptor-Positive, HER2-Negative Breast Cancer
Sep 13, 2022
When given as a first treatment, the combination of dalpiciclib — a new CDK4/6 inhibitor —with either Arimidex or Femara improved progression-free survival in women diagnosed with advanced-stage, hormone receptor-positive, HER2-negative breast cancer. Read more...0 -
People With Metastatic HER2-Low Breast Cancer Report How Enhertu Affected Their Quality of Life
Sep 13, 2022
Patient-reported outcomes from the DESTINY-Breast04 study, which looked at using the targeted therapy Enhertu to treat metastatic HER2-low breast cancer, suggest Enhertu controls pain better than doctors' choice of chemotherapy. Read more...0
